UK Urged To Fund Rare Disease Treatments Immediately
Executive Summary
Genetic Alliance UK says companies should be clear about how they price rare disease treatments and that the government should explain how it assesses affordability.
You may also be interested in...
England’s New Innovative Medicines Fund ‘Must Be Future Proof’
When establishing the new fund, lessons should be learned from the Cancer Dugs Fund so other disease areas are not neglected, say experts.
UK: NICE’s Rare Disease Gatekeeping Comes Under The Microscope
A judicial review of how health technology appraisal body NICE decided which appraisal route BioMarin’s rare disease drug Kuvan would take could have lasting implications for future treatments.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.